Compare Amcor PLC (AMCR) vs Davita Inc (DVA) Price & Performance

Amcor PLCTrade

Davita IncTrade

Price performance (Past 24H)

Key statistics

Amcor PLC vs Davita Inc — how do they compare? Amcor PLC trades at $46.79 (market cap $21.92B), while Davita Inc trades at $179.02 (market cap $11.38B). The key difference: Amcor PLC is the larger of the two by market cap, and Amcor PLC pays a 5.49% dividend while Davita Inc pays none. Which is the better fit depends on your goals.

	AMCR	DVA
Market Cap	$21.92B	$11.38B
Sector	Basic Materials	Health
52-Week High	$50.58	$240.96
52-Week Low	$36.69	$103.87
Enterprise Value	$37.03B	$24.10B
Dividend Yield	5.49%	—

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

AMCR

Amcor reports 57% sales growth and $1.1B net income in FY 2026, boosted by Berry acquisition.PRNewsWire · 5 hours agoBullish View details →

DVA

Berkshire Hathaway cuts cash reserves, boosts stock buybacks and equity investments under new CEO Greg Abel.CNBC · 3 days agoBullish View details →

About Amcor PLC

Amcor is a global plastics packaging behemoth, with global sales of USD 14.5 billion in fiscal 2022 following the acquisition of Bemis in 2019. Amcor's operations span over 40 countries globally and include significant emerging-market exposure equating to circa 20% of sales. Amcor's capabilities span flexible and rigid plastic packaging, which sell into defensive food, beverage, healthcare, household, and personal-care end markets.

About Davita Inc

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.